Fuji Pharma Co Ltd
TSE:4554

Watchlist Manager
Fuji Pharma Co Ltd Logo
Fuji Pharma Co Ltd
TSE:4554
Watchlist
Price: 1 756 JPY 1.74%
Market Cap: 43.7B JPY

Fuji Pharma Co Ltd
Cash & Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Fuji Pharma Co Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Fuji Pharma Co Ltd
TSE:4554
Cash & Cash Equivalents
ÂĄ6.9B
CAGR 3-Years
15%
CAGR 5-Years
-10%
CAGR 10-Years
2%
Takeda Pharmaceutical Co Ltd
TSE:4502
Cash & Cash Equivalents
ÂĄ681.5B
CAGR 3-Years
-5%
CAGR 5-Years
2%
CAGR 10-Years
1%
Daiichi Sankyo Co Ltd
TSE:4568
Cash & Cash Equivalents
ÂĄ542.2B
CAGR 3-Years
4%
CAGR 5-Years
4%
CAGR 10-Years
9%
Otsuka Holdings Co Ltd
TSE:4578
Cash & Cash Equivalents
ÂĄ492.1B
CAGR 3-Years
1%
CAGR 5-Years
8%
CAGR 10-Years
0%
Chugai Pharmaceutical Co Ltd
TSE:4519
Cash & Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Astellas Pharma Inc
TSE:4503
Cash & Cash Equivalents
ÂĄ287.1B
CAGR 3-Years
-7%
CAGR 5-Years
0%
CAGR 10-Years
-3%
No Stocks Found

Fuji Pharma Co Ltd
Glance View

Market Cap
42.9B JPY
Industry
Pharmaceuticals

Fuji Pharma Co., Ltd. engages in the development, manufacture and sale of pharmaceutical products. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 1,532 full-time employees. The firm is engaged in the manufacture and sale of hormone medicines for obstetrics and gynecology department, as well as injectable drugs for radiological department such as radiopaque dye for urinary tracts and blood vessels through its branches. In addition, the Company purchases its main pharmaceutical ingredients from its main parent company.

Intrinsic Value
2 283.9 JPY
Undervaluation 23%
Intrinsic Value
Price

See Also

What is Fuji Pharma Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
6.9B JPY

Based on the financial report for Jun 30, 2025, Fuji Pharma Co Ltd's Cash & Cash Equivalents amounts to 6.9B JPY.

What is Fuji Pharma Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
2%

Over the last year, the Cash & Cash Equivalents growth was 156%. The average annual Cash & Cash Equivalents growth rates for Fuji Pharma Co Ltd have been 15% over the past three years , -10% over the past five years , and 2% over the past ten years .

Back to Top